Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Novo Nordisk shuts cell therapy unit amid restructuring

Published by Global Banking and Finance Review

Posted on October 10, 2025

Featured image for article about Headlines

By Siddhi Mahatole

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Bloomberg News first reported on the development earlier in the day, citing Danish newspaper Borsen, which said Novo was also laying off nearly all of the unit's 250 employees.

Novo was testing its cell therapy to generate insulin-producing beta cells for patients with type 1 diabetes in a preclinical study, along with another cell therapy candidate for Parkinson's disease in early-stage trials.

The company said last month it would cut 9,000 jobs in a bid to reignite growth and revive its fortunes under a new CEO.

"As part of this change, we are assessing all business areas and regions to simplify structures, reduce duplication, and sharpen focus," a Novo spokesperson said on Friday, but declined to share details about individual sites and employees involved.

The drugmaker said it was seeking partners with manufacturing capacity to develop its innovations.

It has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, Reuters reported earlier this week, citing a review of LinkedIn posts.

In late September, Novo called off its $598 million collaboration with Japanese biotech Heartseed to develop cell therapy for patients with advanced heart failure.

(Reporting by Siddhi Mahatole and Sneha S K in Bengaluru; Editing by Shailesh Kuber, Alan Barona, Sahal Muhammed and Pooja Desai)